Stool Softener Market Report 2026

The stool softener market size has grown strongly in recent years. It will grow from $1.81 billion in 2025 to $1.94 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to chronic constipation prevalence, aging demographics, opioid-induced constipation cases, increased otc availability, physician prescribing habits.

The stool softener market size is expected to see strong growth in the next few years. It will grow to $2.51 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising geriatric population, growth in home healthcare, demand for gentle laxatives, increased awareness of digestive health, expanding retail pharmacy networks. Major trends in the forecast period include plant-based formulations, sugar-free laxatives, flavored oral dosage forms, combination stool softeners, pediatric-friendly products.

The rising prevalence of gastrointestinal disorders is expected to drive growth in the stool softener market in the coming years. Gastrointestinal disorders encompass any condition affecting the gastrointestinal tract, including the mouth, esophagus, stomach, small intestine, large intestine, and anus. Factors such as poor diet, lack of exercise, and stress contribute to the increasing incidence of these disorders. Stool softeners help manage gastrointestinal conditions by making stools easier to pass, preventing constipation, and reducing strain during bowel movements. For example, in 2023, Crohn's and Colitis Canada, a Canada-based non-profit organization, reported that the number of people in Canada with IBD is projected to rise from 322,600 in 2023 (0.8% of the population) to 470,000 in 2035 (1.1% of the population). In 2023, approximately 11,000 new cases were diagnosed (1 every 48 minutes), increasing to 14,000 by 2035 (1 every 38 minutes). Therefore, the growing prevalence of gastrointestinal disorders is fueling growth in the stool softener market.

Leading companies in the stool softener market are focusing on developing innovative products, such as Ayurvedic liquid laxatives, to provide natural and gentle relief options for consumers. Ayurvedic liquid laxatives are herbal-based formulations designed to alleviate constipation by promoting gentle bowel movements, combining traditional Ayurvedic ingredients known for their digestive benefits to support overall gut health. For instance, in December 2023, Lupin Limited, an India-based pharmaceutical company, launched Softovac Liquifibre. This 100% Ayurvedic liquid laxative combines Isabgol fiber with natural ingredients like Sonamukhi and Harad, offering effective relief from constipation. The product is clinically validated for safety and efficacy, is gentle, non-habit-forming, and suitable for daily use, including for diabetics, due to its sugar-free formulation.

In June 2023, Atlantis Consumer Healthcare Inc., a US-based pharmaceutical company, acquired the Colace, Senokot, Betadine, and SlowMag brands from Avrio Health L.P. for an undisclosed amount. This acquisition strengthens Atlantis’s position as a leader in health and wellness and allows the company to enhance the well-being of a larger consumer base. Avrio Health L.P., based in the US, specializes in stool softeners.

Major companies operating in the stool softener market are F. Hoffmann-La Roche Ltd., Bayer AG, AstraZeneca Plc., Abbott Laboratories Inc., Takeda Pharmaceutical Company Ltd., GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Solvay S.A., Teva Pharmaceutical Industries Ltd., Mylan N.V., Purdue Pharma L.P., Mallinckrodt Plc, Aristo Pharma GmbH, Raptakos Brett Co. Ltd., Unipex Group Inc., Chemo Biological, Angiolife Healthcare Pvt. Ltd., Iscon Life Sciences, Starmed Pvt. Ltd., Phaedrus Ltd., Stadmed Pvt. Ltd., Avrio Health L.P., Healwell, Velnex Medicare, Sanify Healthcare Pvt. Ltd.

North America was the largest region in the stool softener market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stool softener market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the stool softener market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the stool softener market by increasing the cost of imported active ingredients, pharmaceutical excipients, packaging materials, and softgel capsules. Retail pharmacies and hospitals in Asia-Pacific and emerging regions are most affected due to reliance on global pharmaceutical supply chains. These higher costs can raise OTC and prescription product prices. However, tariffs are encouraging domestic drug formulation and packaging, improving long-term affordability.

The stool softener market research report is one of a series of new reports that provides stool softener market statistics, including stool softener industry global market size, regional shares, competitors with a stool softener market share, detailed stool softener market segments, market trends and opportunities, and any further data you may need to thrive in the stool softener industry. This stool softener market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A stool softener is a type of laxative that works by increasing the water content in the intestines, making stool easier to pass without straining. It is commonly used to treat mild constipation and is often recommended for individuals who need to avoid straining during bowel movements, such as post-surgery patients. Stool softeners are typically used short-term for occasional constipation and are available both over-the-counter (OTC) and by prescription.

The main types of stool softeners include liquid and softgel capsules. Liquid stool softeners are available in liquid form and can be taken orally or used rectally to ease bowel movements. Stool softeners are available as medicines or procedures, with oral and rectal modes of administration. They are accessible both OTC and by prescription and are used by various end users, including hospitals, clinics, home care services, and others.

The stool softener market consists of sales of docusate sodium, docusate calcium, liquid gels, and fiber supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.